Addex Signs Agreement with Sinntaxis for Exclusive Rights to mGlu5 Inhibitors in Brain Injury Recovery
Wednesday, April 30, 2025
Addex Therapeutics, a clinical-stage biopharmaceutical company listed on SIX and NASDAQ, has entered into an option and collaboration agreement with Sinntaxis AB for exclusive rights to use intellectual property related to the treatment of brain injury recovery using mGlu5 inhibitors.
The agreement includes a joint research effort, where Sinntaxis will assess Addex’s drug candidate, dipraglurant. This compound is an orally active negative allosteric modulator (NAM) targeting the metabotropic glutamate receptor subtype 5 (mGlu5), and is being explored for its potential to support recovery after brain injuries such as stroke or trauma.
Dipraglurant is one of Addex’s key clinical assets. The collaboration is intended to complete preclinical validation using models of brain injury recovery, building on earlier published findings. Previous clinical studies in other conditions have demonstrated dipraglurant to be safe, well tolerated, and highly selective for the mGlu5 receptor, making it a strong candidate for further development in neurological recovery.
As part of the deal, Addex will pay Sinntaxis an undisclosed option fee to secure access to its intellectual property. Sinntaxis will also support the research by contributing to the design and execution of both preclinical and clinical plans.
Recovery from stroke typically depends on the brain's ability to form new or restore existing neural connections. Research has shown that the mGlu5 receptor plays an important role in brain plasticity and function. A study published in BRAIN indicated that 12 days of treatment with mGlu5 NAMs, starting shortly after a stroke, helped restore sensory function without affecting the size of the brain lesion. The treatment improved limb use and reversed disruptions in brain connectivity, particularly in sensorimotor and visual regions.
This collaboration aims to advance dipraglurant into clinical trials for patients recovering from brain injuries.
Source: addextherapeutics.com
